EQL Pharma Feed

2026-07-15 09:57:44 EQL Pharma: Mellozzan® (melatonin) approved in Kazakhstan

2026-07-15 09:57:44 EQL Pharma: Mellozzan® (melatonin) godkänt i Kazakstan

2026-07-13 14:40:45 EQL Pharma: Memprex© (metenaminhippurat) licensavtal tecknat med partner för Spanien 22,90 SEK | -1,93% | 0,77 MSEK

2026-07-13 14:40:45 EQL Pharma: Memprex© (methenamine hippurate) license signed with partner for Spain 22,90 SEK | -1,93% | 0,77 MSEK

2026-07-10 13:25:06 Inbjudan till presentation i samband med EQL Pharmas delårsrapport, första kvartalet, 2026/27 23,35 SEK | -2,30% | 1,38 MSEK

2026-07-10 13:25:06 Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2026/27 23,35 SEK | -2,30% | 1,38 MSEK

2026-06-15 11:18:37 EQL Pharma: Metenaminhippurat (varumärket Cystohipp©) har lanserats i Tyskland 25,40 SEK | +3,46% | 2,97 MSEK

2026-06-15 11:18:37 EQL Pharma: Methenamine hippurate (brand name Cystohipp©) has been launched in Germany 25,40 SEK | +3,46% | 2,97 MSEK

2026-05-08 07:00:00 Bokslutskommuniké april 2025 - mars 2026 30,65 SEK | -42,39% | 38,0 MSEK

2026-05-08 07:00:00 Year-end Report April 2025 - March 2026 30,65 SEK | -42,39% | 38,0 MSEK

2026-04-27 13:12:49 EQL Pharma i process att rekrytera ny Chief Supply Chain Officer (CSCO) 50,30 SEK | -0,79% | 0,79 MSEK

2026-04-27 13:12:49 EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO) 50,30 SEK | -0,79% | 0,79 MSEK

2026-04-22 13:01:54 Inbjudan till presentation i samband med EQL Pharmas Bokslutskommuniké, fjärde kvartalet, 2025/26 51,40 SEK | -1,91% | 0,85 MSEK

2026-04-22 13:01:54 Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2025/26 51,40 SEK | -1,91% | 0,85 MSEK

2026-03-27 16:48:50 EQL Pharmas VD säljer aktier för att finansiera kapitalvinstskatt från optionsinlösen 50,80 SEK | -4,33% | 2,20 MSEK

2026-03-27 16:48:50 EQL Pharma CEO sells shares to finance capital gains tax from option redemption 50,80 SEK | -4,33% | 2,20 MSEK

2026-03-25 10:36:09 EQL Pharma: Mellozzan® (melatonin) har blivit godkänt i Italien 53,00 SEK | +3,11% | 1,41 MSEK

2026-03-25 10:36:09 EQL Pharma: Mellozzan® (melatonin) has been approved in Italy 53,00 SEK | +3,11% | 1,41 MSEK

2026-02-12 13:22:05 EQL Pharma: Valberedning inför årsstämman 2026 63,80 SEK | -1,39% | 2,07 MSEK

2026-02-12 13:22:05 EQL Pharma: Nomination committee for the 2026 Annual General Meeting 63,80 SEK | -1,39% | 2,07 MSEK

2026-02-03 14:15:00 Kommuniké från extra bolagsstämma i EQL Pharma AB den 3 februari 2026 60,00 SEK | -6,69% | 8,68 MSEK

2026-02-03 14:15:00 Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026 60,00 SEK | -6,69% | 8,68 MSEK

2026-02-03 12:30:00 EQL Pharma: Delårsrapport April - december 2025 60,00 SEK | -6,69% | 8,68 MSEK

2026-02-03 12:30:00 EQL Pharma: Interim Report April - December 2025 60,00 SEK | -6,69% | 8,68 MSEK

2026-01-15 11:40:06 Inbjudan till presentation i samband med EQL Pharmas delårsrapport, tredje kvartalet, 2025/26 56,40 SEK | +6,02% | 2,37 MSEK

2026-01-15 11:40:06 Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26 56,40 SEK | +6,02% | 2,37 MSEK

2026-01-07 13:29:05 Kallelse till extra bolagsstämma i EQL Pharma AB 57,20 SEK | +1,60% | 2,46 MSEK

2026-01-07 13:29:05 Notice of extraordinary general meeting in EQL Pharma AB 57,20 SEK | +1,60% | 2,46 MSEK

2025-12-04 10:00:00 EQL Pharma rekryterar Anne D Jensen som ny försäljningschef (CSO) och Carl Lindgren lämnar sin position som affärsutvecklingschef (CBDO) 49,45 SEK | -2,08% | 1,12 MSEK

2025-12-04 10:00:00 EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO) 49,45 SEK | -2,08% | 1,12 MSEK

2025-12-03 14:36:20 EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO) 50,50 SEK | -0,39% | 1,32 MSEK

2025-12-03 14:36:20 EQL Pharma rekryterar Allan Sylvest Aasberg som ny Chief Financial Officer (CFO) 50,50 SEK | -0,39% | 1,32 MSEK

2025-11-17 13:57:27 EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm 54,60 SEK | +0,74% | 1,87 MSEK

2025-11-17 13:57:27 EQL Pharma AB (publ) offentliggör prospekt och ansöker om upptagande till handel av obligationer på Nasdaq Stockholms företagsobligationslista 54,60 SEK | +0,74% | 1,87 MSEK

2025-11-14 13:49:42 EQL Pharma: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany 54,20 SEK | +3,83% | 1,21 MSEK

2025-11-14 13:49:42 EQL Pharma: Metenamin hippurat (varumärke Cystohipp©) har fått marknadsföringsgodkännande i Tyskland 54,20 SEK | +3,83% | 1,21 MSEK

2025-11-05 07:00:00 EQL Pharma: Halvårsrapport April - september 2025 55,00 SEK | -10,28% | 9,04 MSEK

2025-11-05 07:00:00 EQL Pharma: Interim Report April - September 2025 55,00 SEK | -10,28% | 9,04 MSEK

2025-10-22 11:27:26 Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2025/26 57,30 SEK | -2,22% | 1,04 MSEK

2025-10-22 11:27:26 Inbjudan till presentation i samband med EQL Pharmas delårsrapport, andra kvartalet, 2025/26 57,30 SEK | -2,22% | 1,04 MSEK

2025-10-06 15:08:26 EQL Pharma in process of recruiting new Chief Commercial Officer (CCO) 62,50 SEK | -4,87% | 4,69 MSEK

2025-10-06 15:08:26 EQL Pharma i process att rekrytera ny Chief Commercial Officer (CCO) 62,50 SEK | -4,87% | 4,69 MSEK

2025-09-30 10:00:00 Change in number of shares and votes in EQL Pharma AB 66,00 SEK | -3,65% | 1,67 MSEK

2025-09-30 10:00:00 Ändring av antalet aktier och röster i EQL Pharma AB 66,00 SEK | -3,65% | 1,67 MSEK

2025-09-23 14:59:26 EQL Pharma: Mellozzan® (melatonin) launched in the UK 66,60 SEK | -13,17% | 36,0 MSEK

2025-09-23 14:59:26 EQL Pharma: Mellozzan® (melatonin) lanserat i Storbritannien 66,60 SEK | -13,17% | 36,0 MSEK

2025-09-22 22:35:00 EQL Pharma: Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected 66,60 SEK | -13,17% | 36,0 MSEK

2025-09-22 22:35:00 EQL Pharma: Leveransförseningar gör att andra kvartalet och därmed helåret 2025/26 blir svagare än väntat 66,60 SEK | -13,17% | 36,0 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode